Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2010

Genetic Targeting of ERK1 Suggests a Predominant Role for ERK2
in Murine Pain Models
Benedict J. Alter
Washington University School of Medicine in St. Louis

Chengshui Zhao
Washington University School of Medicine in St. Louis

Farzana Karim
Washington University School of Medicine in St. Louis

Gary E. Landreth
Case Western Reserve University

Robert W. Gereau IV
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Alter, Benedict J.; Zhao, Chengshui; Karim, Farzana; Landreth, Gary E.; and Gereau, Robert W. IV, ,"Genetic
Targeting of ERK1 Suggests a Predominant Role for ERK2 in Murine Pain Models." The Journal of
Neuroscience. 30,34. 11537-11547. (2010).
https://digitalcommons.wustl.edu/open_access_pubs/233

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

The Journal of Neuroscience, August 25, 2010 • 30(34):11537–11547 • 11537

Behavioral/Systems/Cognitive

Genetic Targeting of ERK1 Suggests a Predominant Role for
ERK2 in Murine Pain Models
Benedict J. Alter,1 Chengshui Zhao,1 Farzana Karim,1 Gary E. Landreth,2 and Robert W. Gereau IV1
1
2

Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, and
Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

The extracellular signal-regulated kinase (ERK) isoforms, ERK1 and ERK2, are believed to be key signaling molecules in nociception and
nociceptive sensitization. Studies using inhibitors targeting the shared ERK1/2 upstream activator, mitogen-activated protein kinase
kinase (MEK), and transgenic mice expressing a dominant-negative form of MEK have established the importance of ERK1/2 signaling.
However, these techniques do not discriminate between ERK1 and ERK2. To dissect the function of each isoform in pain, we used mice
with a targeted genetic deletion of ERK1 [ERK1 knock-out (KO)] to test the hypothesis that ERK1 is required for behavioral sensitization
in rodent pain models. Despite activation (phosphorylation) of ERK1 after acute noxious stimulation and in models of chronic pain, we
found that ERK1 was not required for formalin-induced spontaneous behaviors, complete Freund’s adjuvant-induced heat and mechanical hypersensitivity, and spared nerve injury-induced mechanical hypersensitivity. However, ERK1 deletion did delay formalin-induced
long-term heat hypersensitivity, without affecting formalin-induced mechanical hypersensitivity, suggesting that ERK1 partially
shapes long-term responses to formalin. Interestingly, ERK1 deletion resulted in elevated basal ERK2 phosphorylation. However,
this did not appear to influence nociceptive processing, since inflammation-induced ERK2 phosphorylation and pERK1/2 immunoreactivity in spinal cord were not elevated in ERK1 KO mice. Additionally, systemic MEK inhibition with SL327 (␣-[amino[(4aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile) attenuated formalin-induced spontaneous behaviors similarly
in wild-type and ERK1 KO mice, indicating that unrelated signaling pathways do not functionally compensate for the loss of ERK1.
Together, these results suggest that ERK1 plays a limited role in nociceptive sensitization and support a predominant role for ERK2 in
these processes.

Introduction
Extracellular signal-regulated kinases (ERKs), ERK1 and ERK2,
are mitogen-activated protein kinases (MAPKs) (Pearson et al.,
2001) that have been identified as critical players in sensitization
to noxious stimuli after peripheral inflammation and nerve damage (Ji et al., 1999, 2002; Karim et al., 2001; Ciruela et al., 2003;
Obata et al., 2003; Song et al., 2005). A variety of acute noxious
stimuli and chronic pain models result in ERK1/2 activation
(phosphorylation) at many levels of the nociceptive sensory system including dorsal root ganglion (DRG), spinal cord, and
amygdala (Ji et al., 2009). The use of inhibitors that block activation of both ERK1 and ERK2 by inhibiting their shared upstream
MAP kinase kinases (MEK1/2) and transgenic expression in neurons of a dominant-negative form of MEK1, which suppresses
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MEK1/2–ERK1/2 signaling, have demonstrated that ERK1/2 is
necessary for nociceptive sensitization (Ji et al., 1999, 2002, 2009;
Karim et al., 2001, 2006; Song et al., 2005; Hu et al., 2006; Seino et
al., 2006).
Although much is known about MEK1/2–ERK1/2 signaling,
little is known about the specific functions of each ERK isoform.
Functional redundancy has been a working model because the
isoforms are 90% homologous (Boulton et al., 1991) and no
isoform-specific inhibitors currently exist. However, there is
emerging evidence that ERK1 and ERK2 may be functionally
distinct. ERK1 knock-outs (ERK1 KOs) are viable but exhibit
behavioral abnormalities correlated with altered synaptic plasticity in striatum (Pagès et al., 1999; Selcher et al., 2001; Mazzucchelli et al., 2002), whereas ERK2 knock-outs are embryonic lethal
at embryonic day 8.5 (Krens et al., 2006). Alternative methods for
targeting ERK2, including reduced expression from a hypomorphic mutant allele and conditional deletion in telencephalon,
have revealed a requirement for ERK2 in several learning and
memory paradigms (Satoh et al., 2007; Samuels et al., 2008). In
cell culture, genetic targeting or RNA interference (RNAi) experiments suggest specific roles for ERK1 and ERK2 (Mazzucchelli et
al., 2002; Vantaggiato et al., 2006). Evidence to support this hypothesis includes the observations that ERK1 exclusively interacts with the MEK–ERK signaling scaffold MP1 (Schaeffer et al.,
1998) and the fact that differences in amino acid sequence between ERK1 and ERK2 occur in domains that may affect MEK1/2

11538 • J. Neurosci., August 25, 2010 • 30(34):11537–11547

binding, ERK dimerization, and subcellular localization (Boulton et al., 1991; Zhang et al., 1994; Cobb and Goldsmith, 2000).
Indeed, ERK1 and ERK2 have different rates of shuttling between
the cytoplasm and nucleus because of sequence differences in the
N terminus (Marchi et al., 2008).
Currently, the importance of ERK1 in nociceptive sensitization remains unknown. Therefore, we tested the necessity of
ERK1 in acute noxious sensitization and in models of chronic
inflammatory and neuropathic pain using ERK1 KO mice. Although ERK1 is activated in these models, genetic deletion of
ERK1 had a minimal impact on these ERK-dependent behaviors.
Interestingly, ERK1 deletion increased basal ERK2 phosphorylation without affecting inflammation-induced changes in ERK2
phosphorylation. Our observations indicate that ERK1 is not required for nociceptive sensitization and suggest that ERK2 plays a
predominant role.

Materials and Methods
Animals. All experiments were performed according to the guidelines of
the National Institutes of Health and were approved by the Animal Care
and Use Committee of Washington University School of Medicine. Mice
were housed with a 12 h light/dark cycle and ad libitum access to food and
water. Targeted deletion of ERK1 was achieved by homologous recombination in a process described in detail previously (Nekrasova et al.,
2005). Briefly, the targeting vector deleted exons 1– 6 of mapk3, which
includes the kinase active site and phosphorylation loop, and replaced
them with a Neo cassette flanked with loxP sites. Embryonic stem cells
from 129 Sv mice were transfected and selected for homologous recombination. Successfully targeted clones were injected into CD1 blastocysts,
which were implanted in pseudopregnant CD1 females. Chimeras with
germ-line transmission were obtained on the CD1 background. The
mapk3 mutation was subsequently transferred to the C57BL/6 background by backcrossing ⬎10 times. C57BL/6 mapk3 mutant heterozygotes were crossed, producing mice heterozygous for the mapk3 mutant
allele, homozygous for the mutant allele (ERK1 KO), and homozygous
for the wild-type mapk3 allele (WT). Seven- to 9-week-old ERK1 KO and
WT male littermates from these crosses were used in all experiments. The
experimenter was blind to the genotype and treatment in all behavioral
experiments.
Measurement of heat and mechanical thresholds. All behavioral tests
were performed in rooms isolated from other activity and with white
noise present. Tests were conducted at room temperature (⬃25°C) during the second half of the light cycle. Before testing, mice were allowed to
acclimate to the behavioral room and apparatus for 2–3 h. After acclimation, measurements of paw withdrawal thresholds to heat and mechanical stimuli were performed. Measurements were consistently made when
mice were calm. Modular clear Plexiglas behavior chambers (width, 10
cm; length, 10 cm; height, 15 cm), which could be placed on different
floor surfaces, were used with one mouse per chamber. Responses to heat
were measured using a modified Hargreaves test (Hargreaves et al.,
1988). Mice were placed in behavior chambers on a 390G Plantar Test
Apparatus (IITC Life Science) with a glass plate floor heated to ⬃30°C.
Radiant heat was applied to the plantar surface of the hindpaw using a
focused beam of light with an active intensity of 14% maximal, a cutoff of
20 s, and idle intensity of 5% maximal. The 100% beam intensity heats to
⬃250°C. To measure paw withdrawal latency, a timer was automatically
initiated at the onset of heat application (active intensity), and on paw
withdrawal, the heat source was returned to idle intensity automatically
stopping the timer. Five independent measurements, separated by 15
min alternating between right and left paws, were used to determine
baseline withdrawal latency. For time points hours after paw injections,
two independent measurements were averaged. On subsequent days,
three independent measurements were used. To measure responses to
mechanical stimuli, mice were placed in behavioral chambers on an elevated wire mesh floor. Calibrated von Frey filaments (North Coast Medical) were then applied through the mesh to the plantar surface of the
hindpaw between the anterior and posterior foot pads, except for the
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spared nerve injury (SNI) experiment in which filaments were applied to
the lateral surface of the hindpaw in sural nerve territory. Filaments were
pressed into the skin until the filament bent, held for ⬃1 s, and then
removed. Withdrawal of the hindpaw from the mesh indicated a positive
withdrawal response. Each filament was applied five times at a frequency
of ⬃0.5 Hz. The lightest filament (0.008 g) was initially used followed by
progressively heavier filaments until the filament that evoked three withdrawals out of five applications was reached. The calibrated force of the
filament was recorded as the paw withdrawal threshold. Three to five
independent measurements were averaged to yield the baseline threshold
for each hindpaw. Hours after paw injections, a single measurement was
used, whereas on subsequent days, three independent measurements
were averaged for each time point.
Formalin-induced spontaneous behaviors. To measure spontaneous behavioral responses to formalin injection, mice were acclimated in behavior chambers with a Plexiglas floor for at least 1 h. Mice were then injected
subcutaneously with 10 l of 2% formalin (Sigma-Aldrich) in sterile
0.9% NaCl into the plantar surface of the hindpaw and immediately
returned to the behavior chamber. Total time spent licking and lifting
the injected paw was recorded in 5 min bins for 1 h. In experiments
with the MEK inhibitor, ␣-[amino[(4-aminophenyl)thio]methylene]-2(trifluoromethyl)benzeneacetonitrile (SL327) (Tocris Bioscience), mice
were allowed to acclimate as above, injected with SL327 or vehicle
(DMSO), and then returned to the behavior chamber. Thirty minutes
later, mice were injected into the plantar surface of the hindpaw with
3.5% formalin, returned to the behavior chamber, and video recorded
from below with a webcam (Logitech) at a resolution of 960 ⫻ 720 for 1 h
without the experimenter present. Subsequently, videos were scored for
time spent licking, lifting, and flinching the injected paw.
Formalin and complete Freund’s adjuvant-induced hypersensitivity.
Formalin-induced hypersensitivity to heat and mechanical stimuli was
used as a model of persistent pain. Heat hypersensitivity to formalin
was assayed by measuring baseline paw withdrawal latencies using a
Hargreaves-style apparatus as described above on day 1. On day 2, mice
were acclimated (2–3 h) and injected with 10 l of 2% formalin (in sterile
0.9% NaCl). Threshold measurements from the injected (ipsilateral) and
uninjected (contralateral) paws were made at 1, 2, and 3 h after injection.
On subsequent postinjection days, mice were first allowed to acclimate
(2–3 h), and then paw withdrawal thresholds were obtained. To measure
mechanical hypersensitivity to formalin, a similar time course was performed except von Frey filaments were used as detailed above. Intraplantar injections of 10 l of 3.5% formalin (in sterile 0.9% NaCl) were made
and subsequent threshold measurements were obtained. A higher concentration of formalin was used in mechanical experiments because 2%
formalin did not produce robust mechanical hypersensitivity in either
WT or ERK1 KO mice (data not shown). Intraplantar injection of complete Freund’s adjuvant (CFA) (10 l, 1.0 mg/ml; Sigma-Aldrich) was
used as a chronic inflammatory pain model. The same experimental
design used in formalin-induced hypersensitivity experiments was used
to assay mechanical and heat hypersensitivity after CFA injection.
Spared nerve injury model. To measure mechanical hypersensitivity
after spared nerve injury (Decosterd and Woolf, 2000), paw withdrawal
thresholds from the lateral surface of each hindpaw were obtained using
von Frey filaments with the up– down method (Chaplan et al., 1994).
Baseline thresholds were measured on day 1 after 2–3 h of acclimation on
wire mesh. On day 2, mice were anesthetized with pentobarbital, a small
incision in the thigh was made, and the three main branches of the sciatic
nerve were exposed. The common peroneal and tibial nerves were ligated
with 8-0 silk suture and cut distal to ligation. One millimeter of distal
nerve stump was removed, and the surgical wound was closed with 7 mm
surgical clips. After 3 d of recovery, clips were removed. To measure
mechanical hypersensitivity after surgery, mice were acclimated to the
mesh (2–3 h), and mechanical withdrawal thresholds were measured
from the sural nerve territory (lateral surface of hindpaw).
Sample preparation and Western blot analysis. Mice were placed individually in cages and allowed to acclimate for 2–3 h to approximate
behavioral testing conditions. For formalin and CFA experiments, mice
were then injected subcutaneously into the plantar surface of the hindpaw with 10 l of 3.5% formalin or vehicle (0.9% NaCl) in formalin
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experiments or 10 l of CFA or 0.9% NaCl in CFA experiments. Mice
were then killed using a guillotine, and spinal cords were rapidly removed
by hydraulic extrusion. In dose-finding experiments with SL327, mice
were acclimated as above, injected with SL327 or vehicle (DMSO), returned to their cage for 30 min, injected with 3.5% formalin, and killed 3
min after paw injection. Spinal cord levels lumbar 3– 6 (L3–L6) were
isolated, and ipsilateral and contralateral sides were separated. For CFA
experiments, the dorsal half was isolated and flash-frozen on dry ice. For
formalin experiments, the entire dorsoventral extent was flash-frozen. In
experiments with uninjected mice, the lumbar enlargement was isolated
and flash-frozen without additional dissection. In naive subjects, immediately after spinal cord extraction thoracic and lumbar DRGs were dissected
in ice-cold PBS (Mediatech), pooled into a single sample, and immediately
homogenized. Frozen spinal cord and fresh DRG samples were homogenized using a Dounce homogenizer in ice-cold buffer containing 20 mM Tris,
pH 7.5, 1 mM EDTA, 1 mM Na4P2O7, 25 g/ml aprotinin (Sigma-Aldrich),
25 g/ml leupeptin (Sigma-Aldrich), 100 M PMSF (Roche Applied Science), 1 g/ml microcystin LR (Enzo Life Science), and 1 mM Na3VO4
(Sigma-Aldrich) in Milli-Q distilled water. Protein concentrations were
determined with the BCA protein assay (Pierce Biotechnology) and
SmartSpec 3000 spectrophotometer (Bio-Rad).
Protein homogenates were size separated by SDS-PAGE. For pERK/
ERK or ERK/actin Westerns, 10 g of protein was used. For c-Jun
N-terminal kinase (JNK) and p38 Westerns, 20 g of DRG homogenate
was used, and 20 – 40 g of spinal cord homogenate was used. For formalin and CFA experiments, precast Tris-HCl 4% stacking and 10%
separating polyacrylamide midi-gels were used (Bio-Rad). For experiments with naive mice, 5% stacking and 10% separating polyacrylamide
mini-gels were prepared based on the Laemmli system (Coligan et al.,
2001). Gels were transferred to nitrocellulose membranes using a wet
transfer system (Bio-Rad). Membranes were blocked for 1 h at room
temperature (RT) with Odyssey blocking buffer (LI-COR Biosciences)
and then simultaneously probed with two primary antibodies from different host species for 1 h at RT diluted in blocking buffer unless otherwise noted. Primary antibodies used include anti-pERK1/2 (mouse
monoclonal; 1:1000; Cell Signaling), anti-ERK1/2 (rabbit polyclonal;
1:1000; Cell Signaling), anti-actin (1:2000; mouse monoclonal; SigmaAldrich), anti-JNK (rabbit polyclonal; 1:1000; Cell Signaling), anti-pJNK
(mouse monoclonal; 1:1000; Cell Signaling), anti-p38 (rabbit polyclonal;
1:1000; Cell Signaling), anti-p-p38 (mouse monoclonal; 1:500; primary
incubation for 4 h at RT; Cell Signaling), and anti-␤-tubulin (mouse
monoclonal; 1:20,000; Sigma-Aldrich). After several washes, membranes
were then incubated for 1 h at RT with fluorescently conjugated secondary antibodies goat anti-rabbit IRDye800 (1:20,000; LI-COR Biosciences) and goat anti-mouse Alexa Fluor 680 (1:20,000; Invitrogen),
which were detected with the Odyssey Infrared Fluorescence Imaging
System (LI-COR Biosciences) for simultaneous detection of 700 and 800
nm wavelength fluorescent emissions corresponding to mouse and rabbit primary antibodies, respectively. Densitometry of bands in 700
(pERK1/2, pJNK, p-p38, ␤-tubulin, or actin) and 800 (ERK1/2, JNK,
p38) channels was performed using the Odyssey Infrared Fluorescence
Imaging System software (LI-COR Biosciences).
Immunohistochemistry. Mice were placed individually in cages and
allowed to acclimate for 2–3 h to approximate behavioral testing conditions. Three minutes after formalin injection (10 l; 3.5% in 0.9% NaCl),
mice were overdosed with Avertin anesthesia (1.25% working solution in
0.9% NaCl diluted from a stock of 1.0 mg/ml 2,2,2-tribromoethanol in
tert-amyl alcohol, both from Sigma-Aldrich) by intraperitoneal injection. Mice were then transcardially perfused at a rate of 15–20 ml per
minute with warm (⬃37°C) PBS and then 150 ml of ice-cold paraformaldehyde (4% in PBS). Spinal cord was isolated, rinsed in PBS overnight at
4°C, and then cryoprotected in 30% sucrose/PBS for 2 d at 4°C. Transverse 30 m sections were obtained using a cryostat and collected in
ice-cold PBS. Floating sections were then stained for pERK1/2 using
3,3⬘-diaminobenzidine (DAB) secondary detection. All incubations were
performed with gentle agitation at RT, unless otherwise noted, with several washes between steps. Endogenous peroxidase activity was suppressed by incubating in 10% methanol, 0.3% H2O2 (in PBS) for 30 min.
Sections were blocked with 1% normal goat serum/0.02% Triton X-100
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in PBS (1% NGST) for 1 h, and then incubated in anti-pERK1/2 (1:3000
in 1% NGST; rabbit polyclonal; Cell Signaling) overnight at 4°C. Sections
were removed from 4°C and allowed to warm to RT for 1 h, after which
sections were incubated with biotinylated goat anti-rabbit IgG (1:200 in
1% NGST; Vector Laboratories) for 1 h and then extrAvidin peroxidase
(1:1000 in 1% NGST; Sigma-Aldrich) for 1 h. Finally, sections were incubated for 6 min with a DAB solution supplemented with nickel prepared from a DAB substrate kit (Vector Laboratories). Sections were
placed on microscope slides and dehydrated by exposing slices to ethanol/water solutions with progressively increasing concentrations of ethanol and finally CitriSolv (Thermo Fisher Scientific). After dehydration,
slides were coverslipped with distrene plasticizer xylene mounting media
(Electron Microscopy Sciences). Bright-field and dark-field images were
captured with a 10⫻ objective using an Olympus compound microscope
with a Photometrics CoolSnap HQ monochrome camera. Bright- and
dark-field images from the same field were then superimposed in Photoshop (version 7.0; Adobe) and the lamina II–III boundary was traced
on the dark-field image. The boundary was then applied to the bright-field
image, and the resultant image was used to count positively staining cell
profiles in lamina I–II using NIH ImageJ, version 1.42. During imaging and
quantification, the experimenter was blind to genotype. Color images were
obtained using a NanoZoomer automated microscope (Hamamatsu).
Statistical analysis. Statistical analysis was performed using Excel (Microsoft) and Prism (GraphPad Software). Details of specific statistical
tests are included in Results. Graphs showing means and SEM were
graphed using Prism.

Results
Baseline sensory function remains normal in ERK1 KO mice
Although a large body of evidence indicates that ERK1/2 is important in nociception, little is known about the relative contribution of each individual isoform. To assess the role of ERK1 in
nociceptive sensory function, we used mice with a targeted deletion of mapk3 (ERK1 KO), in which part of exon 1 and all of
exons 2– 6 are replaced with a pPGKneolox cassette (Nekrasova et
al., 2005). Deletion of ERK1 was confirmed by Western blots of
spinal cord and DRG tissue obtained from ERK1 KO mice (Fig.
1 A, B). As expected, ERK1 immunoreactivity was undetectable in
ERK1 KO mice (Fig. 1 A, B) (unpaired t test, ***p ⬍ 0.001). Deletion of ERK1 had no effect on ERK2 protein expression (unpaired t test). These data confirm previous findings that ERK1
protein is eliminated from the CNS (Selcher et al., 2001; Nekrasova et al., 2005) and extends these findings to the peripheral
nervous system by demonstrating ERK1 deletion without altered
ERK2 expression.
After confirming the absence of ERK1 in important nociceptive anatomic loci, we measured the baseline sensory function of
ERK1 KO mice. The latency to paw withdrawal from a radiant
heat source was comparable between ERK1 KO and WT mice
(Fig. 1C). Additionally, paw withdrawal thresholds to mechanical
stimulation with von Frey filaments in ERK1 KO mice were similar to WT littermates (Fig. 1C). In both cases, there was no statistically significant difference between WT and ERK1 KO mice
(unpaired t test). Both sensory tests rely on reflexive withdrawal
of the hindlimb to measure threshold responses. Since alterations
in motor function secondary to ERK1 deletion could confound
the results of these tests, we also screened the ERK1 KO mice for
motor abnormalities. We found no difference in the performance
of ERK1 KO and WT mice on the accelerating rotarod task or in
exploratory behaviors in an open-field task (supplemental Fig.
S1, available at www.jneurosci.org as supplemental material).
Overall, these results indicate that genetic disruption of ERK1
does not affect baseline withdrawal responses from heat or mechanical stimuli.

11540 • J. Neurosci., August 25, 2010 • 30(34):11537–11547

Alter et al. • ERK1 in Pain Models

Figure 2. Formalin-induced spontaneous nociceptive responses are preserved in ERK1 KO
mice. The amount of time spent in spontaneous nociceptive behaviors after 2% formalin injection (licking and lifting of the injected paw) was recorded from WT (n ⫽ 16) and ERK1 KO (n ⫽
14) littermates and plotted in 5 min bins. No statistically significant difference between WT and
ERK1 KO was detected over the course of the 60 min trial or in total time spent in the first phase
(0 –5 min, bottom left graph) or second phase (5– 40 min, bottom right graph) of nociceptive
behaviors. Error bars represent SEM.
Figure 1. Disruption of mapk3 eliminates ERK1 expression in spinal cord and dorsal root
ganglion without affecting heat or light touch thresholds. A, Spinal cords were isolated from WT
(n ⫽ 13) and ERK1 KO (n ⫽ 14) littermates and analyzed by Western blot for ERK1/2 and the
loading control, actin. To quantify the intensity of ERK bands, integrated intensities of each
isoform were divided by actin integrated intensities and plotted as fold WT. B, DRGs from WT
(n ⫽ 7) and ERK1 KO (n ⫽ 8) were dissected and analyzed by quantitative Western blot as in A.
In both spinal cord and DRGs, there is a dramatic reduction in ERK1 expression without a significant change in ERK2 protein levels. C, No differences were observed in heat thresholds obtained
by applying radiant heat to the hindpaws of WT (n ⫽ 10) and ERK1 KO (n ⫽ 10) littermates
using a Hargreaves-style apparatus. No differences were observed in hindpaw mechanical withdrawal thresholds obtained with von Frey filaments from WT (n ⫽ 14) and ERK1 KO (n ⫽ 13)
littermates. Error bars indicate SEM. ***p ⬍ 0.001, unpaired t test.

ERK1 is not required for first or second phases of the
formalin test
Previous reports indicate that spinal ERK1 is activated (phosphorylated) within minutes after intraplantar injection of the
noxious chemical formalin and that inhibition of spinal ERK1/2
using intrathecally applied MEK inhibitors reduces the second
phase of spontaneous formalin-induced nociceptive behaviors (Ji
et al., 1999; Karim et al., 2001). Therefore, we hypothesized that
ERK1 was necessary for full expression of spontaneous nociceptive behaviors after formalin injection. Surprisingly, ERK1 KO
and WT littermates have indistinguishable formalin responses
(Fig. 2). Both WT and ERK1 KO show a stereotypical biphasic
response characterized by an immediate increase in licking and
lifting (first phase), which subsides momentarily but gradually
increases and persists over the after ⬃30 min (second phase).
There is no statistically significant difference between genotypes
when considering the complete time course of the formalin response [two-way repeated-measures (RM) ANOVA: F ⫽ 0.64,

DFn ⫽ 1, DFd ⫽ 308, p ⫽ 0.4304]. Moreover, the amount of time
spent in nociceptive behaviors in the first phase (0 –5 min) and
the second phase (5– 40 min) is similar between the genotypes
(Fig. 2, unpaired t test). Overall, these data indicate that, even in
the absence of ERK1, formalin can induce robust spontaneous
behaviors that have previously been shown to require ERK1
and/or ERK2, suggesting a specific role for ERK2 in this process.
ERK1 KO mice develop robust hypersensitivity in long-term
inflammatory and neuropathic pain models
ERK1 and/or ERK2 contribute to the development and maintenance of chronic inflammatory and neuropathic pain (Ji et al.,
2009). To directly assess the contribution of ERK1 from all tissues
to CFA-induced hypersensitivity, ERK1 KO mice were injected
with CFA into the hindpaw and examined for hypersensitivity to
radiant heat and mechanical stimuli over time. ERK1 KO mice
became robustly hypersensitive to radiant heat applied to the
paw ipsilateral to CFA injection (Fig. 3A). The degree of hypersensitivity in ERK1 KO mice was comparable with WT littermate controls (two-way RM ANOVA: F ⫽ 1.38, DFn ⫽ 1,
DFd ⫽ 90, p ⫽ 0.2562). In the contralateral paw, there was no
statistically significant hypersensitivity over time (two-way RM
ANOVA: F ⫽ 1.96, DFn ⫽ 5, DFd ⫽ 90, p ⫽ 0.0923). Moreover,
there was no statistically significant difference between the genotypes (two-way RM ANOVA: F ⫽ 2.26, DFn ⫽ 1, DFd ⫽ 90, p ⫽
0.1504). CFA injection also produced dramatic hypersensitivity
to mechanical stimulation that was indistinguishable between
WT and ERK1 KO littermates (Fig. 3B). There was no statistically
significant difference between genotypes in withdrawal thresholds in the ipsilateral paw (two-way RM ANOVA: F ⫽ 0.86,
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Figure 4. ERK1 KO and WT littermates develop similar mechanical hypersensitivity after
peripheral nerve injury. One day after baseline measurements, WT (n ⫽ 9) and ERK1 KO (n ⫽
10) littermates were anesthetized, and the tibial and common peroneal branches of the sciatic
nerve were ligated then transected, leaving the sural branch intact. After the spared nerve injury
surgery, paw mechanical withdrawal thresholds were measured ipsilateral (solid lines) and
contralateral (dashed lines) to nerve injury. Baseline and postinjury withdrawal thresholds were
determined by probing the lateral plantar surface of the paw, which is innervated by the sural
nerve. Data are represented as percentage baseline within each subject. Error bars indicate SEM.

Figure 3. ERK1 is not necessary for CFA-induced hypersensitivity. A, To measure CFAinduced heat hypersensitivity, WT (n ⫽ 10) and ERK1 KO (n ⫽ 10) littermates were injected
with CFA subcutaneously into the plantar surface of the hindpaw. Paw withdrawal latencies to
a radiant heat stimulus were then obtained from both hindpaws, ipsilateral and contralateral to
CFA injection, using a Hargreaves-style apparatus. Data were normalized to preinjection baseline paw withdrawal latencies within subject and plotted as percentage baseline. B, To measure
CFA-induced mechanical allodynia, WT (n ⫽ 6) and ERK1 KO (n ⫽ 6) littermates were injected
with CFA, and paw withdrawal thresholds to light touch were measured using von Frey filaments. In all cases, there was no statistically significant difference between genotypes. Error
bars indicate SEM.

DFn ⫽ 1, DFd ⫽ 70, p ⫽ 0.3761) or the contralateral paw (twoway RM ANOVA: F ⫽ 4.41, DFn ⫽ 1, DFd ⫽ 70, p ⫽ 0.062).
Overall, these data indicate that ERK1 KO mice show normal
sensitization to mechanical and heat stimuli in the CFA model of
long-term inflammatory pain.
The mechanisms driving nociceptive sensitization in neuropathic pain are often distinct from inflammatory pain. Indeed,
the time course and anatomic localization of ERK1/2 phosphorylation is different between neuropathic (Obata et al., 2004;
Zhuang et al., 2005) and inflammatory (Ji et al., 2002; Obata et al.,
2003) pain models. However, the relative importance of ERK1 or
ERK2 in neuropathic pain remains unknown. To address this
issue, we measured the responses of ERK1 KO mice in the SNI
model, in which two branches of the sciatic nerve are transected
(tibial and common peroneal branches), leaving the third
branch, the sural nerve, intact. In skin innervated by the sural
nerve ipsilateral to SNI, ERK1 KO and WT mice developed equivalent, robust mechanical hypersensitivity (Fig. 4). In the contralateral paw, withdrawal thresholds remained unchanged
relative to baseline. There is no statistically significant difference
between ERK1 KO and WT littermates in withdrawal thresholds
ipsilateral (two-way RM ANOVA: F ⫽ 0.05, DFn ⫽ 1, DFd ⫽
102, p ⫽ 0.8263) or contralateral (two-way RM ANOVA: F ⫽
0.89, DFn ⫽ 1, DFd ⫽ 102, p ⫽ 0.3591) to the nerve injury. These
results indicate that ERK1 KO mice are equally susceptible to
SNI-induced mechanical hypersensitivity as WT littermates,
suggesting that ERK1 is not required in this model of neuropathic pain.

ERK1 KO mice show reduced heat hypersensitivity after
intraplantar injection of formalin
Intraplantar injection of formalin produces well characterized
immediate spontaneous behaviors, which give way to hypersensitivity to heat and mechanical stimuli hours after the injection
(Fu et al., 2001; Zeitz et al., 2004; Hu et al., 2006). Inhibition of
ERK1/2 activation in the amygdala has no effect on immediate
spontaneous behaviors but, instead, dramatically reduces
long-term formalin-induced hypersensitivity (Carrasquillo
and Gereau, 2007). Therefore, we reasoned that, although there
was no apparent role of ERK1 in formalin-induced spontaneous
nociceptive behaviors, ERK1 may be involved in longer-term
formalin-induced hypersensitivity. To test this hypothesis, we
injected ERK1 KO and WT littermates with formalin and measured responses to heat and mechanical stimuli. Interestingly,
ERK1 KO mice showed attenuated heat hypersensitivity 1 and 2 h
after 2% formalin injection in the ipsilateral paw (Fig. 5A). A
two-way repeated-measures ANOVA confirmed this difference,
indicating a significant main effect of genotype (F ⫽ 9.69; DFn ⫽
1; DFd ⫽ 56; p ⫽ 0.0076) with a Bonferroni post test revealing a
significant difference at 1 and 2 h time points ( p ⬍ 0.05). Neither
WT nor ERK1 KO mice developed heat hypersensitivity in the
contralateral paw. At the same time points after 3.5% formalin
injection, ERK1 KO mice developed robust mechanical hypersensitivity ipsilateral to injection that was similar to WT littermates (Fig. 5B). Although 1 and 3 h time points appear elevated in
ERK1 KO mice, there is no statistically significant difference between the genotypes (two-way RM ANOVA: F ⫽ 3.81, DFn ⫽ 1,
DFn ⫽ 60, p ⫽ 0.0700). It is important to note that we used 3.5%
formalin to measure mechanical hypersensitivity. In WT mice
obtained from ERK1 heterozygous crosses, 2% formalin did not
produce robust mechanical hypersensitivity (data not shown).
Using 2% formalin, we observed no difference between ERK1 KO
and WT littermates (data not shown). Overall, these data indicate
that ERK1 KO mice do not fully express formalin-induced heat
hypersensitivity, despite normal formalin-induced mechanical
hypersensitivity.
Deletion of ERK1 elevates ERK2 phosphorylation without
affecting ERK2 expression
ERK1 and ERK2 are both phosphorylated by MEK1/2, giving rise
to the possibility that eliminating one ERK isoform might alter
the phosphorylation state of the remaining isoform. The effect of
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Figure 5. ERK1 contributes to the onset of heat hypersensitivity after intraplantar formalin
injection. A, To assess the role of ERK1 in long-term formalin-induced heat hypersensitivity, WT
(n ⫽ 8) and ERK1 KO (n ⫽ 8) littermates were injected with 2% formalin subcutaneously into
the plantar side of the right hindpaw. Paw withdrawal latencies were measured before and
after injection and are graphed as percentage of preinjection baseline. ERK1 KO mice have
reduced hypersensitivity to heat at 1 and 2 h after formalin injection in the ipsilateral paw
(two-way RM ANOVA with Bonferroni’s post test, *p ⬍ 0.05). B, To measure formalin-induced
mechanical hypersensitivity, WT (n ⫽ 8) and ERK1 KO (n ⫽ 9) littermates were injected with
3.5% formalin. Paw withdrawal thresholds were obtained using von Frey filaments. There were
no statistically significant differences between WT and ERK1 KO. Error bars reflect SEM.

ERK1 deletion on ERK2 phosphorylation in spinal cord or DRG
remains unknown. Therefore, we analyzed tissue from naive WT
and ERK1 KO mice by Western blot to size separate the isoforms
and quantify the basal phosphorylation state of each isoform independently (Fig. 6 A). Interestingly, ERK1 KO mice have significantly elevated basal ERK2 phosphorylation compared with WT
littermates in both spinal cord and DRG. It is important to note
that, in these tissues, total ERK2 expression remains unaltered
(Fig. 1). To determine whether the activity of structurally related
MAP kinases may be affected by ERK1 deletion, we analyzed
spinal cord and DRG homogenates from naive WT and ERK1 KO
littermates for JNK and p38 expression and phosphorylation
(Fig. 6 B–D). No significant difference was detected between
ERK1 KO and WT homogenates, suggesting that altered basal
p38 or JNK activity cannot account for the minimal behavioral
impact of ERK1 deletion. Overall, these data do indicate that, in
spinal cord and DRG, ERK1 elimination results in enhanced
basal phosphorylation of ERK2.
Inflammation-induced elevation of pERK2 is equivalent
between ERK1 KO and WT littermates
Given that ERK2 phosphorylation is elevated in naive ERK1 KO
mice, we hypothesized that noxious stimulation would lead to
hyperphosphorylation of ERK2. To test this hypothesis, ERK1
KO and WT mice were injected with either formalin or saline and
killed at the peak of formalin-induced ERK1/2 phosphorylation
in spinal cord (3 min after injection) (Fig. 7A). After normalizing
to the total ERK loading control, ipsilateral intensities were di-
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vided by contralateral intensities within each subject, to provide a
within-animal control. As previously reported (Karim et al.,
2001), injection of WT mice with formalin significantly increased
pERK1 and pERK2 compared with WT saline-injected mice (Fig.
7A) (for pERK1: unpaired t test, p ⬍ 0.001; for pERK2: two-way
ANOVA, F ⫽ 55.92, DFn ⫽ 1, DFd ⫽ 20, p ⬍ 0.0001). ERK1 KO
mice also show significant elevation of pERK2 after formalin injection (two-way ANOVA: F ⫽ 55.92, DFn ⫽ 1, DFd ⫽ 20, p ⬍
0.0001). Interestingly, there is no significant difference between
WT and ERK1 KO littermates in formalin-induced pERK2 increases (two-way ANOVA: F ⫽ 2.11, DFn ⫽ 1, DFd ⫽ 20, p ⫽
0.1617). These data suggest that ERK1 deletion does not affect the
change in spinal ERK2 phosphorylation attributable to formalininduced inflammation. Similar results were obtained when using
the CFA model of inflammation (Fig. 7B). WT and ERK1 KO
littermates were injected with CFA or saline and killed at the peak
time point of CFA-induced ERK1/2 phosphorylation (30 min
after injection) (Ji et al., 2002). Western blot analysis of the dorsal
portion of L3–L6 spinal cords indicated a significant increase in
ipsilateral pERK1 for WT and pERK2 for both WT and ERK1 KO
mice injected with CFA compared with saline-injected mice
(pERK1: unpaired t test, p ⬍ 0.001; pERK2: two-way ANOVA,
F ⫽ 21.02, DFn ⫽ 1, DFd ⫽ 17, p ⫽ 0.0003). This CFA-induced
increase in pERK2 was not different between WT and ERK1 KO
mice (two-way ANOVA: F ⫽ 0.13, DFn ⫽ 1, DFd ⫽ 17, p ⫽
0.7202). Similar results were obtained by normalizing pERK/ERK
values to WT saline (supplemental Figs. S2, S3, available at www.
jneurosci.org as supplemental material). Using this alternative
analysis, ERK1 KO mice have elevated pERK2 in all conditions
compared with WT littermates. However, the relative increase in
pERK2 attributable to formalin or CFA appears similar between
WT and ERK1 KO, as is reflected in Figure 7. Overall, these data
indicate that ERK1 deletion does not affect inflammationinduced elevation of pERK2.
Formalin-induced pERK1/2 immunostaining is slightly
reduced in ERK1 KO mice
Although increases in pERK2 after noxious stimulation appear
unaffected by ERK1 deletion, it is possible that the anatomic
localization of pERK2 is altered which may reflect compensatory
changes in nociceptive circuitry arising from the loss of ERK1
during development. To address this, ERK phosphorylation was
measured by immunohistochemistry with a phosphospecific
ERK1/2 antibody, since current antibodies cannot discriminate
between pERK1 and pERK2 because of high sequence homology
in the phosphorylation loop. ERK1 KO mice were injected with
formalin and L3–L4 spinal cord sections were stained for
pERK1/2. Interestingly, formalin-injected ERK1 KO mice had a
similar pattern of pERK1/2 immunoreactivity to WT littermates
(Fig. 8 A). For both genotypes, positively staining cell profiles and
more diffuse fiber staining was evident in the superficial lamina
of the dorsal horn ipsilateral to paw injection. The dorsoventral
or mediolateral extent of pERK1/2 immunostaining was not appreciably different between genotypes. To quantify pERK1/2
staining, all pERK1/2-positive cell profiles found in the superficial dorsal horn (lamina I and lamina II), as defined by dark-field
illumination, were counted from serial sections separated by at
least 90 m (Fig. 8 B). In both WT and ERK1 KO littermates,
significantly more pERK1/2-positive cell profiles appear ipsilateral to formalin injection than contralateral (two-way ANOVA:
F ⫽ 56.68, DFn ⫽ 1, DFd ⫽ 4, p ⫽ 0.0017). Interestingly, the
number of pERK1/2-positive cell profiles ipsilateral to formalin
injection is significantly reduced in ERK1 KO mice compared
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we sought to test whether MEK inhibition
could reduce formalin-induced spontaneous nociceptive behaviors in ERK1 KO
mice, as has been reported in WT mice
(Karim et al., 2001). Previous studies have
used intrathecal delivery of MEK inhibitors. Since ERK1 is eliminated in all tissues
of the ERK1 KO and since ERK1/2 activity
is important for nociceptive sensitization
in areas in addition to spinal cord, a more
appropriate test would involve systemic
MEK inhibition. SL327 is a structural analog of U0126 [1,4-diamino-2,3-dicyano1,4-bis(2-aminophenylthio)butadiene]
that is blood-brain barrier permeable and
has previously been used to inhibit MEK
in the brain by systemic intraperitoneal
administration (Atkins et al., 1998). However, it has not yet been used in the formalin
test and has not been evaluated in spinal
cord. Thus, we began our study by determining the dose of SL327 required to maximally inhibit formalin-induced ERK1/2
phosphorylation in spinal cord (Fig. 9A).
Pretreatment with both 30 and 50 mg/kg
SL327 intraperitoneally 30 min before
3.5% formalin injection to the hindpaw
significantly reduced pERK1 and pERK2
in spinal cord tissue ipsilateral and contralateral to the injected paw (one-way
ANOVA: pERK1 ipsi, F ⫽ 14.9, DFn ⫽ 3,
DFd ⫽ 11, p ⫽ 0.0012; pERK2 ipsi, F ⫽
29.85, DFn ⫽ 3, DFd ⫽ 11, p ⬍ 0.0001;
pERK1 contra, F ⫽ 15.23, DFn ⫽ 3,
DFd ⫽ 11, p ⫽ 0011; pERK2 contra, F ⫽
36.42, DFn ⫽ 3, DFd ⫽ 11, p ⬍ 0.0001).
Therefore, we used 50 mg/kg SL327 to
Figure 6. In spinal cord and DRG, basal ERK2 phosphorylation increases in the absence of ERK1. A, Spinal cord (SC) homogenates
from naive WT (n ⫽ 7) and ERK1 KO (n ⫽ 8) littermates were analyzed simultaneously for pERK1/2 and ERK1/2 by quantitative evaluate the effect of systemic MEK inhiWestern blot. Although there is no difference in total ERK2 expression in ERK1 KO spinal cord (Fig. 1), ERK2 phosphorylation is bition on the formalin test in both WT
significantly elevated. Similar results were observed in whole-cell homogenates prepared from DRG (WT, n ⫽ 7; ERK1 KO, n ⫽ 8; and ERK1 KO littermates (Fig. 9B). SL327
unpaired t test, *p ⬍ 0.05). B–D, The same spinal cord and DRG homogenates were used to evaluate the expression and at 50 mg/kg significantly attenuated forphosphorylation of related MAPKs, JNK and p38. The integrated intensities of JNK2/3, JNK1, and p38 bands were divided by malin-induced spontaneous nociceptive
corresponding loading control ␤-tubulin bands, normalized to the mean WT intensity, and expressed as fold WT. To evaluate behaviors in WT mice (two-way RM
phosphorylation, pJNK2/3, pJNK1, and p-p38 bands were divided by their corresponding total protein bands from the same ANOVA: F ⫽ 8.09, DFn ⫽ 1, DFd ⫽ 198,
samples, normalized, and then expressed as fold WT. No significant difference was detected between WT and ERK1 KO mice in p ⫽ 0.0108). Importantly, no difference
either spinal cord or DRG (WT SC, n ⫽ 7; ERK1 KO SC, n ⫽ 8; WT DRG, n ⫽ 5; ERK1 KO DRG, n ⫽ 6; unpaired t test). WT data are
was detected between WT and ERK1 KO
represented with white bars, and ERK1 KO data are represented with gray bars. Error bars indicate SEM.
mice injected with SL327 (two-way RM
ANOVA: F ⫽ 0.91, DFn ⫽ 1, DFd ⫽ 187,
with WT littermates (two-way ANOVA: F ⫽ 9.79, DFn ⫽ 1,
p ⫽ 0.3528). Vehicle-injected ERK1 KO and WT littermates also
DFd ⫽ 8, p ⫽ 0.0141). This likely reflects the loss of ERK1 phosbehaved similarly (two-way RM ANOVA: F ⫽ 0.08, DFn ⫽ 1,
phorylation after formalin, which is normally seen in WT mice
DFd ⫽ 165, p ⫽ 0.7795), recapitulating results from Figure 2 in
(Fig. 7). Importantly, in ERK1 KO mice formalin-induced
animals injected with DMSO. Overall, these data indicate that
pERK1/2 immunostaining is not elevated and does not occur in
systemic MEK inhibition reduces spontaneous nociceptive behavior
unexpected laminae of the dorsal horn. Both observations would
in the formalin test regardless of ERK1 deletion, suggesting that
argue against the potential confounds of ERK2 hyperphosphorycompensation from MEK-independent signaling pathways in ERK1
lation or developmental remodeling of nociceptive circuitry.
KO is negligible.
MEK inhibition attenuates formalin-induced spontaneous
behaviors similarly in WT and ERK1 KO littermates
Although we observed no change in p38 or JNK expression or
phosphorylation with ERK1 deletion, it remains possible that
other signaling pathways compensate for the loss of ERK1 in the
context of nociceptive sensitization. To address this possibility,

Discussion
Although it is clear that ERK1 and/or ERK2 drive behavioral
sensitization in many pain models, little is known about the relative contribution of each isoform and whether they are redundant. This study is the first to address directly the role of ERK1 in
rodent models of pain by characterizing the nociceptive function
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of ERK1 KO mice. We found that acute
sensitivity to both noxious heat and the noxious chemical, formalin, remains intact despite the loss of ERK1 from all tissues. ERK1
deletion does not affect hypersensitivity attributable to chronic inflammation or nerve
injury. Interestingly, long-term formalininduced hypersensitivity to heat is slightly
reduced by ERK1 deletion. Together, these
data suggest ERK1 is not required for nociceptive sensitization.
Accumulating evidence from this study
and elsewhere strongly suggests that spinal
ERK2, and not ERK1, is critical for CFAinduced hypersensitivity. Targeting ERK1/2
nonspecifically with intrathecally applied
MEK inhibitors attenuates CFA-induced
hypersensitivity (Ji et al., 2002; Obata
et al., 2003). Interestingly, RNAi-mediated
ERK2 knockdown in spinal cord dramatically reduces CFA-induced behavioral sensitization (Xu et al., 2008).
However, because of the partial reduction
of ERK2 expression achieved with this
method, there was a relatively small effect
on ERK2 phosphorylation. ERK2 knockdown also caused an elevation of ERK1
phosphorylation in the spinal cord. In the
physiologically normal context of isoform
coexpression, spinal ERK1 is phosphorylated after CFA injection to the paw (Ji et
al., 2002; Obata et al., 2003; Adwanikar et
Figure 7. Inflammation-induced ERK2 phosphorylation is not elevated in ERK1 KO mice. A, ERK1 KO and WT littermates were
al., 2004; Xu et al., 2008), raising the posinjected subcutaneously into the plantar surface of the hindpaw with saline or 3.5% formalin (n ⫽ 6 per group) and killed 3 min
sibility that ERK1 plays some role in be- later. The dorsoventral extent of L3–L6 spinal cord was isolated and processed for pERK1/2 and ERK1/2 quantitative Western blot
havioral sensitization. The current study analysis. Ipsilateral pERK/ERK intensities were normalized to contralateral intensities from the same subject, and data were
directly addresses this question and demon- graphed as fold contralateral. Formalin injection led to significantly elevated pERK1 and pERK2 in WT mice. In ERK1 KO mice, the
strates that ERK1 deletion has no effect on formalin-induced increase in pERK2 was similar to WT. B, ERK1 KO and WT littermates were injected subcutaneously into the
CFA-induced heat or mechanical hypersen- plantar surface of the hindpaw with saline or CFA (n ⫽ 5– 6 per group). After 30 min, the dorsal halves of L3–L6 spinal cords were
sitivity. Given the combined results of tar- obtained and analyzed for pERK1/2 and ERK1/2 by Western blot as above. As with formalin injection, CFA-injected WT mice had
geting MEK, ERK2, and now ERK1, it is significantly elevated pERK1 and pERK2. Elimination of ERK1 had no significant impact on CFA-induced pERK2 elevation. Error bars
likely that spinal ERK2 specifically drives represent SEM. Unpaired t test or two-way ANOVA with Bonferroni’s post test: *p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001.
CFA-induced hypersensitivity.
haps developmental context given the differences between emIn the present study, we observed that ERK1 deletion is acbryonic cultures and adult mice (Mazzucchelli et al., 2002).
companied by increased ERK2 phosphorylation in the spinal
In all studies using isoform-specific knock-out or knockcord and DRG of naive mice. This could arise if ERK isoforms
down,
the functional importance of ERK isoform hyperphosphonormally compete for binding and phosphorylation with their
rylation is difficult to separate from the effect of deleting the
shared upstream kinase MEK. Without ERK1 expression, MEK
targeted isoform. In ERK1 KO mice, ERK2 hyperphosphorylabinds and exclusively phosphorylates the remaining isoform
tion in striatal cultures is correlated with augmented long-term
ERK2. Similar observations have been made in other systems,
synaptic potentiation in striatum and enhanced place preference
supporting such a model of MEK–ERK1/2 interaction. In NIH/
conditioning for morphine (Mazzucchelli et al., 2002). Similar
3T3 cells, RNAi-mediated knockdown of one isoform elevates the
ERK2 hyperphosphorylation occurs in hippocampal cultures
phosphorylation state of the remaining isoform (Vantaggiato et
from ERK1 KO embryos (Mazzucchelli et al., 2002), but there is
al., 2006; Lefloch et al., 2008). However, the degree of isoform
minimal impact of ERK1 deletion on hippocampal plasticity and,
competition varies with context. In vivo, ERK1 deletion only afbehaviorally, no effect on hippocampus-dependent tasks such as
fects ERK2 phosphorylation in certain non-neuronal tissues,
contextual fear conditioning and passive avoidance (Selcher et
such as the thymus (Nekrasova et al., 2005), but not in hippocamal., 2001). In the present study, elevated ERK2 phosphorylation is
pus, cortex, and striatum (Mazzucchelli et al., 2002). However,
not associated with altered baseline withdrawal responses to noxprimary cultures of cortex or striatum from ERK1 KO embryos
ious heat or mechanical stimulation, and there is no gain-ofexhibit ERK2 hyperphosphorylation after stimulation with either
function in nociceptive sensitization. Additionally, spinal pERK2
glutamate or KCl without altered phosphorylation in untreated
elevation above baseline after intraplantar formalin or CFA is
cultures. It appears that MEK–ERK1/2 interactions depend on
similar between WT and ERK1 KO. This suggests that elevated
cellular context, relative activity of MEK–ERK signaling, and perbasal ERK2 phosphorylation is unrelated to nociceptive sensiti-
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zation. Basal phosphorylation may occur in non-nociceptive cells
of the spinal cord, or it may be an artifact of tissue preparation or
homogenization. In both cases, deletion of ERK1 would lead to
ERK2 hyperphosphorylation only in this non-nociceptivespecific pool of ERK.
An alternative interpretation is that ERK2 hyperphosphorylation actually relates to nociception and functionally compensates
for the loss of ERK1, masking a physiologic role for ERK1. We do
not favor this interpretation for several reasons. First, knockdown of spinal ERK2 also increases basal ERK1 phosphorylation
without affecting baseline sensory responses but with a profound
effect on CFA-induced hypersensitivity (Xu et al., 2008). If ERK
isoforms were interchangeable in the nociceptive spinal cord,
then one would expect ERK1 to compensate for the loss of ERK2,
which did not occur. Second, pERK1/2 immunohistochemistry is
actually reduced in ERK1 KO mice, indicating that elevated
pERK2 cannot make up for the loss of ERK1 in total pERK1/2
immunoreactivity. If isoforms were completely redundant, this
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Figure 8. Noxious peripheral stimulation induces pERK1/2 immunoreactivity in superficial
dorsal horn laminae despite the loss of ERK1. A, Three minutes after subcutaneous intraplantar
injection of 3.5% formalin, WT and ERK1 KO littermates were killed and analyzed for pERK1/2
immunoreactivity in lumbar spinal cord. On the side of the spinal cord ipsilateral to paw injection, pERK1/2-positive cell profiles appear in the superficial lamina of formalin-injected WT and
ERK1 KO mice. Diffuse staining is also apparent, possibly because of ERK1/2 phosphorylation in
dendrites or afferent fibers. In both WT and ERK1 KO, there is no gross difference in the anatomic
pattern of pERK1/2 staining. B, To quantify results from A, pERK1/2-positive cell profiles in
laminae I–II were counted from six sections per animal with three animals per group. The mean
number of cell profiles for each subject was then used to calculate the mean number for the
entire group. Formalin stimulation significantly increases pERK1/2-positive cell profiles in both
WT and ERK1 KO littermates. Two-way ANOVA with Bonferroni’s post test: *p ⬍ 0.05, **p ⬍
0.01. Error bars reflect SEM.
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Figure 9. Systemic MEK inhibition attenuates formalin-induced spontaneous behaviors
similarly in WT and ERK1 KO littermates. A, Several doses of the blood– brain barrier-permeant
MEK inhibitor, SL327, or vehicle (DMSO) were administered intraperitoneally 30 min before
hindpaw intraplantar formalin injection (3.5% in saline). Subjects (n ⫽ 3 per dose) were killed
3 min after formalin injection, and homogenates of spinal cord tissue ipsilateral and contralateral to the paw injection were analyzed for ERK phosphorylation. SL327 significantly reduced
pERK1/ERK1 and pERK2/ERK2 at 30 and 50 mg/kg [one-way ANOVA with Dunnett’s post test
comparing to vehicle (0) within ERK isoform; **p ⬍ 0.01, ***p ⬍ 0.001]. B, ERK1 KO and WT
mice were injected with either vehicle (1 ml/kg DMSO) or 50 mg/kg SL327 intraperitoneally
(WT–vehicle, n ⫽ 9; WT–SL327, n ⫽ 11; KO–vehicle, n ⫽ 8; KO–SL327, n ⫽ 8). After 30 min,
formalin (3.5% in saline) was injected subcutaneously into the plantar surface of the hindpaw,
and spontaneous nociceptive behaviors were measured. SL327 significantly attenuated
formalin-induced nociceptive behaviors in both WT and ERK1 KO littermates (two-way RM
ANOVA with Bonferroni’s post test; asterisks comparing WT–vehicle and WT–SL327, **p ⬍
0.01, ***p ⬍ 0.001; daggers comparing KO–vehicle and KO–SL327, ††p ⬍ 0.01). No significant difference was detected between WT and ERK1 KO mice injected with SL327.

net loss of pERK1/2 would be expected to affect formalininduced spontaneous behaviors. Nevertheless, it remains difficult
to exclude a role for ERK1 without directly testing ERK2 function. The converse is also true, and, as such, the current study
solidifies our understanding of spinal ERK2 function in the CFA
model, as outlined above.
To our knowledge, the present study is the first to examine the
role of ERK isoforms in the formalin model of chemical nociception. Moreover, our experiments with the systemically active
MEK inhibitor, SL327, provide additional evidence that ERK1/2
activity is required for the behavioral response to formalin. Since
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SL327 exerts similar effects in WT and ERK1 KO mice, it seems
likely that ERK2 is specifically required in this behavioral model,
although this must be directly tested. It is tempting to hypothesize that the underlying cellular mechanisms of the formalin test
would also rely on ERK2 and not ERK1. These mechanisms may
include sensitization processes in spinal cord that amplify incoming nociceptive information via enhanced synaptic strength and
intrinsic excitability (Ikeda et al., 2006; Sandkühler, 2009), both
of which involve ERK1/2 (Ji et al., 2009). Formalin also increases
primary afferent activity, which likely contributes to immediate,
phase 1 behavioral responses (Puig and Sorkin, 1996). Since SL327
decreases the first phase of the formalin test and since ERK1 appears
to be dispensable for formalin-induced spontaneous behaviors,
our results predict that ERK2 specifically contributes to elevated
afferent activity, perhaps by increasing excitability via direct phosphorylation of voltage-gated sodium channels (Stamboulian et al.,
2010).
Noxious stimulation or inflammation induces hypersensitivity
to heat, which is primarily attributable to peripheral sensitization of
primary afferent nociceptors (Levine and Alessandri-Haber, 2007).
Previous studies have demonstrated a role for nociceptor ERK1/2 in
inflammation-induced peripheral sensitization using MEK inhibitors (Dai et al., 2002; Obata et al., 2003; Zhuang et al., 2004;
Seino et al., 2006). ERK1/2 may contribute to heat hypersensitivity by modulating TRPV1 (Zhuang et al., 2004; Firner et al.,
2006), which is a molecular sensor of noxious heat that is required for CFA-induced heat hypersensitivity (Caterina et al.,
2000; Levine and Alessandri-Haber, 2007). Our observation that
ERK1 is not required for CFA-induced heat hypersensitivity suggests that ERK2 may specifically modulate TRPV1, a possibility
that must be directly tested. Interestingly, our results also indicate
that formalin-induced heat hypersensitivity is in part mediated
by ERK1. The discrepancy between CFA- and formalin-induced
heat hypersensitivity reported here may be the result of discrete parallel signaling pathways within nociceptive terminals
that are sensitive to either CFA or formalin. Given that ERK1
KO mice develop heat hypersensitivity at later time points after
formalin injection, it is also possible that ERK1 contributes to
heat hypersensitivity but ultimately ERK2 is sufficient to induce
sensitization.
In addition to spinal cord and DRG, ERK1/2 is activated in
many regions of the nociceptive system after noxious stimulation
including the amygdala (Carrasquillo and Gereau, 2007). In
amygdala, microinjection of MEK inhibitors does not affect acute
formalin-induced spontaneous behaviors but does attenuate mechanical hypersensitivity. In the current study, we found that
ERK1 deletion does not affect formalin-induced mechanical hypersensitivity. This fits well with our previous observations that
formalin did not significantly induce ERK1 phosphorylation in
amygdala (Carrasquillo and Gereau, 2007). However, since
amygdala MEK inhibition affected both ERK1 and ERK2 phosphorylation, it was difficult exclude a role for ERK1. The current
study extends our knowledge of the role of the amygdala in nociception by providing evidence that ERK1 is not required for
formalin-induced mechanical hypersensitivity.
Results from the present study indicate that ERK1 is not required
for formalin-induced spontaneous behavior, chronic inflammatory,
and neuropathic pain models, suggesting a predominant isoformspecific role for ERK2. Isoform-specific functions may also occur in
humans, since copy number variation of each isoform yields distinct
neurological deficits. ERK1 deletion or duplication is associated
with autism (Kumar et al., 2008), whereas reduced ERK2 expression is associated with microcephaly, cognitive deficits, and de-

velopmental delay (Newbern et al., 2008). The relevance to the
human nervous system suggests that dissecting the roles of ERK1
and ERK2 will be important for understanding and treating
chronic pain conditions.
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